Order Article Reprints

Bauckneht M, Capitanio S, Donegani MI, Zanardi E, Miceli A, Murialdo R, Raffa S, Tomasello L, Vitti M, Cavo A, et al. Role of Baseline and Post-Therapy 18F-FDG PET in the Prognostic Stratification of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated with Radium-223. Cancers. 2020; 12(1):31. https://doi.org/10.3390/cancers12010031

Bauckneht, Matteo, Selene Capitanio, Maria Isabella Donegani, Elisa Zanardi, Alberto Miceli, Roberto Murialdo, Stefano Raffa, Laura Tomasello, Martina Vitti, Alessia Cavo, and et al. 2020. "Role of Baseline and Post-Therapy 18F-FDG PET in the Prognostic Stratification of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated with Radium-223" Cancers 12, no. 1: 31. https://doi.org/10.3390/cancers12010031

Bauckneht, M., Capitanio, S., Donegani, M. I., Zanardi, E., Miceli, A., Murialdo, R., Raffa, S., Tomasello, L., Vitti, M., Cavo, A., Catalano, F., Mencoboni, M., Ceppi, M., Marini, C., Fornarini, G., Boccardo, F., Sambuceti, G., & Morbelli, S. (2020). Role of Baseline and Post-Therapy 18F-FDG PET in the Prognostic Stratification of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated with Radium-223. Cancers, 12(1), 31. https://doi.org/10.3390/cancers12010031